Cargando…
Oncogenic PKC-ι activates Vimentin during epithelial-mesenchymal transition in melanoma; a study based on PKC-ι and PKC-ζ specific inhibitors
Melanoma is one of the fastest growing cancers in the United States and is accompanied with a poor prognosis owing to tumors being resistant to most therapies. Atypical protein kinase Cs (aPKC) are involved in malignancy in many cancers. We previously reported that aPKCs play a key role in melanoma&...
Autores principales: | Ratnayake, Wishrawana S., Apostolatos, Christopher A., Apostolatos, André H., Schutte, Ryan J., Huynh, Monica A., Ostrov, David A., Acevedo-Duncan, Mildred |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6363030/ https://www.ncbi.nlm.nih.gov/pubmed/29781749 http://dx.doi.org/10.1080/19336918.2018.1471323 |
Ejemplares similares
-
Two novel atypical PKC inhibitors; ACPD and DNDA effectively mitigate cell proliferation and epithelial to mesenchymal transition of metastatic melanoma while inducing apoptosis
por: Ratnayake, Wishrawana S., et al.
Publicado: (2017) -
Analysis of PKC-ζ protein levels in normal and malignant breast tissue subtypes
por: Smalley, Tracess, et al.
Publicado: (2019) -
Coordination of glioblastoma cell motility by PKCι
por: Baldwin, R Mitchell, et al.
Publicado: (2010) -
Inhibition of atypical protein kinase C-ι effectively reduces the malignancy of prostate cancer cells by downregulating the NF-κB signaling cascade
por: Apostolatos, André H., et al.
Publicado: (2018) -
Preclinical testing of 5-amino-1-((1R,2S,3S,4R)-2,3-dihydroxy-4-methylcyclopentyl)-1H-imidazole-4-carboxamide: a potent protein kinase C-ι inhibitor as a potential prostate carcinoma therapeutic
por: Apostolatos, André H., et al.
Publicado: (2019)